ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Lilly Licenses Chinese Compound

by Jean-François Tremblay
October 21, 2013 | APPEARED IN VOLUME 91, ISSUE 42

Eli Lilly & Co. has acquired the China rights for the cancer drug fruquintinib. A kinase inhibitor that may work on several solid tumors, it was discovered and developed by Shanghai-based Hutchison MediPharma. Under their agreement, Lilly and Hutchison will share future costs of developing the compound in China, where it is undergoing Phase II clinical trials. Hutchison could receive up to $87 million in up-front and milestone payments in addition to royalties on any sales of the drug. Lilly and Hutchison have set up several R&D alliances since 2007.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment